viDA's lead candidate, VTI-1002, is a proprietary small-molecule inhibitor of extracellular Granzyme B. The company is pursuing preclinical development programs in dermatology and ophthalmology, supported by research into the role of extracellular GzmB in tissue damage and repair.
Healthy skin repair depends on coordinated inflammation, extracellular-matrix remodeling and restoration of tissue integrity.
When these processes become dysregulated, they can contribute to excessive scarring, persistent inflammation and impaired healing.
Extracellular Granzyme B has been implicated in tissue-remodeling processes that may be relevant to these conditions.
Hypertrophic scars and keloids are characterized by abnormal collagen accumulation and fibrotic tissue remodeling.
These conditions can cause discomfort, itching, functional limitations and substantial cosmetic and psychological burden.
Current treatment approaches include corticosteroid injections, silicone-based treatments, laser therapy, surgery and other interventions. Outcomes vary, and recurrence remains an important clinical challenge.
Extracellular GzmB can cleave proteins involved in extracellular-matrix organization and influence signaling pathways associated with tissue remodeling.
These findings support investigation of GzmB inhibition as a potential approach to pathological scar formation.
viDA is evaluating whether VTI-1002 can modify relevant biological processes and improve outcomes in preclinical models of abnormal scarring.
Development stage: Preclinical
VTI-1002 is viDA's proprietary small-molecule inhibitor of extracellular GzmB.
Building on the compound's prior clinical investigation in dermatology, viDA is advancing indication-specific preclinical development activities to evaluate its potential in pathological scarring and selected skin conditions.
Broader Dermatological Applications
Extracellular GzmB-mediated tissue damage may also be relevant to chronic wounds, pressure injuries, skin fragility and other inflammatory or impaired-healing conditions.
These represent additional research opportunities within viDA's dermatology-focused scientific strategy.
Age-related macular degeneration (AMD) is a major cause of vision impairment, particularly among older adults.
Neovascular AMD is characterized by abnormal blood-vessel growth and leakage that can damage retinal tissues and compromise central vision.
Although anti-VEGF therapies have substantially improved treatment outcomes, important unmet needs remain, including treatment burden and incomplete responses in some patients.
Extracellular Granzyme B has been implicated in processes involving extracellular-matrix degradation, tissue-barrier disruption and inflammatory injury.
These mechanisms may contribute to retinal pathology, including vascular dysfunction and fibrosis.
The biological rationale for GzmB inhibition is distinct from direct VEGF inhibition and may offer opportunities to investigate complementary mechanisms of retinal protection.
Development stage: Preclinical
viDA is evaluating locally delivered VTI-1002 for retinal diseases, with an initial focus on neovascular AMD.
Preclinical research is investigating whether extracellular GzmB inhibition can influence choroidal neovascularization, vascular leakage and associated tissue damage.
The development program includes additional evaluation of efficacy, ocular exposure and target engagement.
A Differentiated Therapeutic Strategy
viDA's objective is to investigate a therapeutic approach that addresses extracellular tissue damage and remodeling associated with retinal disease.
Further preclinical studies are required to establish the translational potential of this approach.